RJA
NEXI

Raymond James & Associates’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Raymond James & Associates’s Portfolio NEXI Stock Details NEXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.7K Hold
10,804
– – ﹤0.01% 3985
2024
Q2 		$29.8K Hold
10,804
– – ﹤0.01% 3850
2024
Q1 		$60.6K Buy
+10,804
New +$83.2K ﹤0.01% 3785
2023
Q4 		– Sell
-12,825
Closed -$67.3K – 3977
2023
Q3 		$67.3K Hold
12,825
– – ﹤0.01% 3649
2023
Q2 		$90.4K Hold
12,825
– – ﹤0.01% 3651
2023
Q1 		$122K Buy
12,825
+11,600
+947% +$122K ﹤0.01% 3606
2022
Q4 		$7.44K Hold
1,225
– – ﹤0.01% 3860
2022
Q3 		$17K Hold
1,225
– – ﹤0.01% 3811
2022
Q2 		$49K Buy
1,225
+400
+48% +$24.8K ﹤0.01% 3792
2022
Q1 		$87K Buy
+825
New +$60.6K ﹤0.01% 3852
2021
Q4 		– Sell
-1,038
Closed -$393K – 4304
2021
Q3 		$393K Buy
+1,038
New +$348K ﹤0.01% 3233

Raymond James & Associates's NEXI Position: Q3 2024 in Review

Raymond James & Associates held its NexImmune, Inc. Common Stock (NEXI) position steady in Q3 2024 at 10,804 shares worth $2.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3985.

Raymond James & Associates first reported a position in NEXI in Q3 2021 and has held it in 11 quarters since. The position peaked at $393K in Q3 2021. 1 fund tracked by Wall St. Rank holds NEXI as of Q3 2024.

  • Raymond James & Associates held 10,804 shares of NexImmune, Inc. Common Stock worth $2.7K as of Q3 2024.
  • Raymond James & Associates left its NexImmune, Inc. Common Stock share count unchanged in Q3 2024.
  • NexImmune, Inc. Common Stock made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3985 holding.
  • Raymond James & Associates first reported a position in NexImmune, Inc. Common Stock in Q3 2021 and has held it in 11 quarters since.
  • Raymond James & Associates's NexImmune, Inc. Common Stock position peaked at $393K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.